Loading...
XNAS
CAPS
Market cap8mUSD
Jul 25, Last price  
1.60USD
1D
-0.31%
1Q
-20.65%
Jan 2017
-97.72%
Name

Capstone Holding Corp

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
0.18
EPS
—
Div Yield, %
—
Shrs. gr., 5y
23.72%
Rev. gr., 5y
%
Revenues
45m
-7.19%
000000045,451,00066,742,99961,561,00048,354,00044,876,000
Net income
-3m
L-32.89%
-3,921,000-4,167,000-2,771,000-663,000-1,755,000-380,000-2,073,00010,455,0003,921,0002,315,000-3,819,000-2,563,000
CFO
4m
+163.70%
-3,951,000-4,094,000-2,153,000-1,209,000-1,561,00066,000-1,679,000642,0003,724,000-2,890,0001,449,0003,821,000

Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
URL
http://www.capstonethx.com/
IPO date
Feb 04, 1993
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
44,876
-7.19%
48,354
-21.45%
61,561
-7.76%
Cost of revenue
35,306
38,743
45,030
Unusual Expense (Income)
NOPBT
9,570
9,611
16,531
NOPBT Margin
21.33%
19.88%
26.85%
Operating Taxes
(442)
234
783
Tax Rate
2.43%
4.74%
NOPAT
10,012
9,377
15,748
Net income
(2,563)
-32.89%
(3,819)
-264.97%
2,315
-40.96%
Dividends
(389)
Dividend yield
Proceeds from repurchase of equity
(389)
BB yield
Debt
Debt current
8,852
12,064
9,162
Long-term debt
3,612
11,292
19,642
Deferred revenue
Other long-term liabilities
36,292
351
3,078
Net debt
12,453
23,304
20,781
Cash flow
Cash from operating activities
3,821
1,449
(2,890)
CAPEX
(120)
(208)
(173)
Cash from investing activities
(120)
(208)
(173)
Cash from financing activities
(3,742)
(1,213)
3,036
FCF
16,068
14,045
10,702
Balance
Cash
11
52
23
Long term investments
8,000
Excess cash
4,945
Stockholders' equity
(196,102)
(163,921)
33,331
Invested Capital
239,625
213,723
57,541
ROIC
4.42%
6.91%
28.39%
ROCE
21.99%
19.30%
26.46%
EV
Common stock shares outstanding
158
158
158
Price
Market cap
EV
EBITDA
10,087
9,917
16,772
EV/EBITDA
Interest
1,483
1,529
895
Interest/NOPBT
15.50%
15.91%
5.41%